NERI and ProMedica team up to offer Ph I-IV research solutions
The firms explained that combining ProMedica’s expertise in Phase I development with the New England Research Institute’s (NERI) experience in later stage studies will provide customers with an integrated trial process and improve efficiency.
The contract research organisations (CRO) highlighted NERI’s study feasibility, protocol design, regulatory affairs and ProMedica’s bioavailability, bioequivalence, pharmacodynamics and toxicity as key strengths of the new alliance.
ProMedica CEO Richard Parker said that: “We know that our Phase I research experience combined with NERI’s Phase II-IV track record will provide our clients with a comprehensive portfolio of services to choose from.
“Through this strategic alliance we offer an expanded and committed team of professionals to tackle any clinical research challenge with consistent standards of excellence.”
Parker’s thoughts were echoed by NERI’s Vice president of clinical research Rebecca Li who suggested that the partnership can “provide expanded CRO services to clinical sponsors that are looking to build long-term relationships.”
Efficiency key for CROs
The NERI and ProMedica collaboration’s focus on efficiency and offering an integrated Phase I to IV development process is particularly timely given the findings of a recent survey by Cutting Edge Research.
Of the 21 drugmakers surveyed, 19 ranked a CRO’s ability to hit deadlines as being “extremely important,” with a significant proportion suggesting that it is even more important a factor than cost.
How the partnership will fare in the global market remains to be seen, especially given the recent disappointing performance of larger rivals like Covance, Charles River and Parexel.
